Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib vs Trastuzumab+Pertuzumab in Adjuvant Breast Cancer
NCT04973319Phase 3Not yet recruiting
- Sponsor
- Shengjing Hospital of China Medical University
- Start
- Aug 2021
- Primary completion
- Aug 2027
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pyrotinib in breast cancer (2 arms), sponsored by Shengjing Hospital of China Medical University. Primary endpoint: Invasive Disease-Free Survival at 3 years. Planned start Aug 2021; status: not yet recruiting.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04973319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973319.